Detalles de la búsqueda
1.
Pre-treatment serum protein levels predict survival of non-small cell lung cancer patients without durable clinical benefit by PD-1/L1 inhibitors.
Cancer Immunol Immunother
; 71(9): 2109-2116, 2022 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-35037070
2.
CD24, not CD47, negatively impacts upon response to PD-1/L1 inhibitors in non-small-cell lung cancer with PD-L1 tumor proportion score < 50.
Cancer Sci
; 112(1): 72-80, 2021 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-33084148
3.
The safety, tolerability and pharmacokinetics of niraparib in Japanese patients with solid tumours: results of a phase I dose-escalation study.
Jpn J Clin Oncol
; 51(5): 693-699, 2021 Apr 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-33621324
4.
Immune-Related Adverse Events by Immune Checkpoint Inhibitors Significantly Predict Durable Efficacy Even in Responders with Advanced Non-Small Cell Lung Cancer.
Oncologist
; 25(4): e679-e683, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-32297443
5.
Predictive value of serum VEGF levels for elderly patients or for patients with poor performance status receiving anti-PD-1 antibody therapy for advanced non-small-cell lung cancer.
Cancer Immunol Immunother
; 69(7): 1229-1236, 2020 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-32152703
6.
Association of immune-related pneumonitis with the presence of preexisting interstitial lung disease in patients with non-small lung cancer receiving anti-programmed cell death 1 antibody.
Cancer Immunol Immunother
; 69(1): 15-22, 2020 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-31745589
7.
Nivolumab-induced autoimmune encephalitis in an anti-neuronal autoantibody-positive patient.
Jpn J Clin Oncol
; 49(8): 793-794, 2019 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31187869
8.
Mannitol versus furosemide in patients with thoracic malignancies who received cisplatin-based chemotherapy using short hydration: A randomized phase II trial.
Cancer Med
; 13(4): e6839, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38457231
9.
A Phase II Study of High-Flow Nasal Cannula for Relieving Dyspnea in Advanced Cancer Patients.
J Pain Symptom Manage
; 67(3): 204-211.e1, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-37992848
10.
Machine learning analysis of pathological images to predict 1-year progression-free survival of immunotherapy in patients with small-cell lung cancer.
J Immunother Cancer
; 12(2)2024 Feb 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-38360040
11.
Adjacent angle size correlates with diagnostic sensitivity of endobronchial ultrasonography with a guide sheath.
J Thorac Dis
; 15(11): 6019-6028, 2023 Nov 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-38090301
12.
Osimertinib as first-line treatment for elderly patients with advanced EGFR mutation-positive non-small cell lung cancer in a real-world setting (OSI-FACT-EP).
Lung Cancer
; 186: 107426, 2023 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-37992594
13.
Pneumonitis associated with pembrolizumab plus chemotherapy for non-squamous non-small cell lung cancer.
Sci Rep
; 13(1): 3698, 2023 03 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36878936
14.
Concurrent High PD-L1 Expression and CD8+ Immune Cell Infiltration Predict PD-1 Blockade Efficacy in Advanced EGFR-Mutant NSCLC Patients.
Clin Lung Cancer
; 23(6): 477-486, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35644780
15.
Impact of pre-existing interstitial lung abnormal shadow on lung injury development and severity in patients of non-small cell lung cancer treated with osimertinib.
Cancer Med
; 11(20): 3743-3750, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35434933
16.
Drug-Related Pneumonitis Induced by Osimertinib as First-Line Treatment for Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer: A Real-World Setting.
Chest
; 162(5): 1188-1198, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-35661746
17.
A phase II study of cisplatin plus vinorelbine combined with atezolizumab as adjuvant therapy for completely resected non-small-cell lung cancer with EGFR mutation (West Japan Oncology Group 11719L/ADJUST study).
Ther Adv Med Oncol
; 13: 1758835920987647, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-33613698
18.
Differential Efficacy of Pembrolizumab According to Metastatic Sites in Patients With PD-L1 Strongly Positive (TPS ≥ 50%) NSCLC.
Clin Lung Cancer
; 22(2): 127-133.e3, 2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33183972
19.
Osimertinib as first-line treatment for advanced epidermal growth factor receptor mutation-positive non-small-cell lung cancer in a real-world setting (OSI-FACT).
Eur J Cancer
; 159: 144-153, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34749119
20.
Association between serum level soluble programmed cell death ligand 1 and prognosis in patients with non-small cell lung cancer treated with anti-PD-1 antibody.
Thorac Cancer
; 11(12): 3585-3595, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-33108686